Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib

Jaramillo, SoniaScherer, MichaelSzu-Tu, ChelseaBeneyto Calabuig, SergiMüller-Tidow, CarstenSchlenk, Richard F.Hundemer, MichaelVelten, LarsPabst, Caroline2025-01-222025-01-222024Jaramillo S, Scherer M, Szu-Tu C, Beneyto-Calabuig S, Müller-Tidow C, Schlenk RF, et al. Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib. Haematologica. 2024 Nov 1;109(11):3811-5. DOI: 10.3324/haematol.2023.2849220390-6078http://hdl.handle.net/10230/69232application/pdfengCopyright (c) 2024 Ferrata Storti Foundation. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).Leucèmia mieloide agudaLate-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegibinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3324/haematol.2023.284922info:eu-repo/semantics/openAccess